Trials / Completed
CompletedNCT01925014
Low vs. Standard Dose CT for Appendicitis Trial
A Multi-institutional Trial Comparing Clinical Outcomes Following Low- vs. Standard-dose Abdominal CT as the First-line Imaging Test in Adolescents and Young Adults With Suspected Acute Appendicitis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 3,074 (actual)
- Sponsor
- Kyoung Ho Lee, MD · Academic / Other
- Sex
- All
- Age
- 15 Years – 44 Years
- Healthy volunteers
- Not accepted
Summary
To determine whether low-dose (LD) CT is noninferior to standard-dose (SD) computed tomography (CT) as the first-line imaging test in adolescents and young adults in regard to negative appendectomy rate (NAR).
Detailed description
* Acute appendicitis is a very common disease. Many patients are adolescents or young adults. * CT is the current standard imaging test for the diagnosis of appendicitis. * In recent years, the awareness of carcinogenic risk associated with CT radiation has increased. * According to a recent single-institutional randomized controlled trial, LD CT (employing a quarter of standard radiation dose) was found to be noninferior to SD CT with respect to NARs in adolescents and young adults with suspected appendicitis. * However, LD CT is not yet widely accepted. * To establish LD CT as the first-line imaging test, a multi-institutional study is needed to confirm the generalizability of the prior single-institutional study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Diagnostic CT with low-dose radiation | Effective dose is aimed at approximately 2 millisievert (mSv) in an average patient. |
| DIAGNOSTIC_TEST | Diagnostic CT with standard-dose radiation | Effective dose is aimed at approximately 8 millisievert (or less) in an average patient. |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2016-12-01
- Completion
- 2017-02-01
- First posted
- 2013-08-19
- Last updated
- 2019-01-31
- Results posted
- 2019-01-31
Locations
20 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01925014. Inclusion in this directory is not an endorsement.